🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — July 15, 2026

The USA M&A & Takeover Activity stream for July 15, 2026, reveals a bifurcated SPAC market: two struggling shells (Ribbon Acquisition Corp., PHP Ventures) are burning cash on extensions, while a new entrant (Samos Energy) and a sponsor-backed vehicle (Yorkville Acquisition Corp.) signal renewed appetite for energy-focused and structured deals. The most material event is Glucotrack's reverse merger with Lōkahi Therapeutics, a high-conviction transaction where Lōkahi will control ~90% of the combined entity, supported by a private placement. Constellation Acquisition Corp I is advancing its HiTech Minerals merger with a scheduled investor event, but lacks financial updates. Nuvalent's post-acquisition filing indicates a completed deal but offers no financial terms, limiting actionable insight. Period-over-period data is sparse across filings, but insider activity (sponsor note conversion) and capital allocation (trust extensions, IPO pricing) provide key signals. The overall theme is a 'survival of the fittest' SPAC environment, with energy and biotech/medtech emerging as preferred sectors.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 15, 2026

Overnight SEC filings reveal a stark bifurcation between companies executing well and those facing existential threats. The most critical theme is a wave of Nasdaq delistings, with five companies (Actelis Networks, American Rebel Holdings, Blue Hat Interactive, Captivision, Sleep Number, and X3 Holdings) all set to be removed from the exchange on July 23, 2026, representing a significant liquidity and reputational blow for shareholders. On the positive side, ASML delivered a standout quarter with Q2 2026 net sales of €9.3 billion and raised its full-year 2026 outlook to between €43 billion and €45 billion, signaling robust demand in the semiconductor capital equipment space. Insider activity was mixed but notable: the CEO of BeOne Medicines sold over $22 million in stock through a 10b5-1 plan, while the CEO of Grab Holdings also sold $1.56 million, creating negative sentiment. Conversely, the CEO of Navios Maritime Partners made small open-market purchases totaling ~$252K, a modestly bullish signal. Capital allocation trends were highlighted by AEON Biopharma's $13.75 million public offering to fund its biosimilar pipeline, and SK hynix's massive $26.5 billion ADR offering, the largest capital raise in the batch. A significant governance event is the activist filing at Tax-Free Fixed Income Fund for Puerto Rico Residents, where a group holding 13.2% of shares is pushing a shareholder proposal. Overall, the data suggests a market rewarding strong operational performance (ASML) while punishing companies with weak fundamentals or compliance issues, with the delisting cluster being the most actionable risk signal.

40 high priority 10 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 14, 2026

This digest covers 8 FDA approvals from July 8-14, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion). The batch is heavily weighted toward established generic entrants, with zero NMEs, zero true biosimilars, and zero significant label expansions; 6 of 8 approvals are rated neutral. Two approvals are flagged as mildly bullish: label expansions for Indocyanine Green injection (PROVEPHARM SAS) and Sodium Bicarbonate (AMNEAL EU LTD), though commercial details are undisclosed. No oncology, neurology, or high-growth therapeutic area clustering is present. The dominant theme is generic competition in mature small-molecule markets, with entrants from Indian and specialty generic houses (Ajanta Pharma, Laurus Labs, Glenmark, Macleods) and hospital supply players (Baxter). The highest-conviction signal is the mild bullish read from the two label expansions, but materiality is low given undisclosed peak sales and exclusivity terms. Key watch items include the lack of NME or novel biologic approvals, signaling a dry period for high-conviction biotech catalysts.

8 total filings
· daily

Big Pharma Approvals — July 14, 2026

This July 14, 2026 digest covers 3 approvals, all classified as 'Other' (non-NME, non-biosimilar, non-standard label expansion), generating 3 bullish signals with no bearish or neutral flags. The dominant theme is oncology, with two label expansions for Merck Sharp & Dohme's pembrolizumab (KEYTRUDA and KEYTRUDA QLEX) and one NME approval for Sanofi-Aventis' isatuximab-irfc (SARCLISA ESCENA) with Orphan Drug designation. The highest-conviction signal is Sanofi's isatuximab-irfc approval, given its NME status and Orphan exclusivity, which strengthens Sanofi's multiple myeloma franchise. Key watch items include the commercial impact of pembrolizumab's expanded indications on Merck's revenue trajectory and the pricing dynamics for isatuximab-irfc in a competitive myeloma landscape.

3 total filings
· daily

Orphan Drug Approvals — July 14, 2026

During this period, the FDA issued two approvals, both classified as 'Other' (non-standard actions), with zero NMEs, biosimilars, or traditional label expansions. The dominant therapeutic area is oncology, with both approvals targeting cancer indications. The highest-conviction signal is the NME approval of ISATUXIMAB-IRFC (SARCLISA ESCENA) by SANOFI-AVENTIS U.S. LLC, granted Orphan Drug designation, which strengthens Sanofi's oncology pipeline and commercial position in multiple myeloma. The second approval is a label expansion for MERCK SHARP DOHME's PEMBROLIZUMAB (KEYTRUDA), reinforcing its market leadership. Key risks include the lack of detailed commercial data (peak sales, pricing, exclusivity) and the potential for accelerated approval-related post-marketing requirements for ISATUXIMAB-IRFC.

2 total filings
· daily

New Drug Approvals (Original) — July 14, 2026

This digest covers 9 FDA approvals from July 8-10, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 9 'Other' approvals (including one NME classified as 'FALLBACK' and several generic/biosimilar-like entries). The dominant therapeutic theme is absent, as approvals span diverse agents (diagnostic dye, electrolyte, oncology monoclonal antibody, diabetes combination, antiviral, antifibrotic, vasopressor, vitamin, and antibacterial). The highest-conviction signal is the NME approval of Sanofi's ISATUXIMAB-IRFC (SARCLISA ESCENA) with Orphan Drug designation, representing a potential new multiple myeloma therapy with premium pricing and 7-year exclusivity. Key risks include the lack of commercial data (peak sales, pricing) for all approvals, and the 'FALLBACK' classification suggests these may be non-standard or supplemental approvals, limiting immediate investment catalysts.

9 total filings
· daily

Federal Construction & Infrastructure Contracts — July 14, 2026

This digest covers a single, large civilian infrastructure contract totaling $224.7 million, awarded by the Department of Homeland Security (DHS) to Fisher Sand & Gravel Co. for border infrastructure construction in Youngtown, AZ. The contract is a firm-fixed-price delivery order with a three-year performance period, and $169.1 million has already been outlaid, indicating strong execution progress. As a private company, Fisher Sand & Gravel presents no direct public equity exposure, but the award underscores sustained investment in border security by DHS/CBP, a politically sensitive area subject to funding volatility. The key risk is potential policy shifts in border security funding, which could affect future awards and the contractor's revenue concentration. No defense-related contracts were recorded in this period, reinforcing a purely civilian infrastructure theme.

1 total filings
· daily

DHS Homeland Security Contracts — July 14, 2026

This digest covers a single $224.7 million civilian contract from the Department of Homeland Security (DHS), specifically U.S. Customs and Border Protection (CBP), awarded to Fisher Sand & Gravel Co. for border infrastructure construction in Youngtown, AZ. The contract is a firm-fixed-price delivery order with a three-year performance period, and $169.1 million has already been outlaid, indicating strong execution progress. The highest-conviction signal is the neutral, revenue-concentrated nature of the award for a private company, with no direct public equity exposure. Key risks include political sensitivity of border security funding and fixed-price cost overruns, while the primary watch item is policy shifts affecting future border infrastructure awards.

1 total filings
· daily

New Federal Contractors — July 14, 2026

This digest covers a single $224.7 million contract awarded to Fisher Sand & Gravel Co. by the Department of Homeland Security (DHS) for border infrastructure construction in Youngtown, AZ. The contract is entirely civilian (0% defense-related) and carries a neutral signal strength of 5/10, reflecting balanced execution progress and political risk. The highest-conviction signal is the $169.1 million already outlaid on the $217.1 million firm-fixed-price delivery order, indicating strong performance but also significant revenue concentration for this private company. Key risks include potential policy shifts in border security funding and cost overruns on a fixed-price contract. No public equity exposure exists, limiting direct investment implications.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 14, 2026

This digest covers a single, large civilian contract modification from July 14, 2026: a $224.7 million firm-fixed-price delivery order awarded to Fisher Sand & Gravel Co. by the Department of Homeland Security (Customs and Border Protection) for border infrastructure construction in Arizona. The contract is entirely civilian, with no defense exposure, and carries a neutral signal due to its fixed-price structure and political sensitivity. The highest-conviction signal is the strong execution progress ($169.1M already outlaid), but the key risk is the concentration of revenue for a private contractor and potential funding volatility tied to border policy shifts. There are no public equity signals from this single award, making it a low-materiality event for institutional investors.

1 total filings
· daily

Contract Deobligations Alert — July 14, 2026

The single contract in this digest, a $224.7 million deobligation alert for Fisher Sand & Gravel Co. from the Department of Homeland Security (DHS/CBP), represents a neutral signal with no direct public equity exposure. The underlying $217.1 million firm-fixed-price delivery order for border infrastructure in Youngtown, AZ, shows strong execution progress with $169.1 million already outlaid, but the deobligation suggests a potential reduction in scope or funding adjustment. As a civilian agency contract in a politically sensitive area, it carries medium execution risk and budget volatility, with no defense-related exposure. The highest-conviction signal is the concentration risk for Fisher Sand & Gravel, a private firm, and the broader theme of sustained but politically cyclical border infrastructure investment.

1 total filings
· daily

Contract Option Exercises — July 14, 2026

The single contract option exercise analyzed for July 14, 2026, totals $224.7 million in obligated funds, entirely civilian (Department of Homeland Security/Customs and Border Protection) with zero defense exposure. The dominant theme is sustained border infrastructure investment, driven by a $217.1 million firm-fixed-price delivery order to Fisher Sand & Gravel Co. for construction in Youngtown, AZ. The highest-conviction signal is neutral: the contract provides predictable revenue for a private contractor but carries medium execution risk due to fixed-price terms and political sensitivity around border funding. A key risk is the potential for policy shifts or continuing resolution volatility affecting future task orders under this IDIQ vehicle.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 14, 2026

This single-contract digest covers a $224.7 million civilian award from the Department of Homeland Security (DHS) to Fisher Sand & Gravel Co. for border infrastructure construction in Youngtown, AZ, with zero defense-related contracts. The neutral signal strength (5/10) and low materiality (3/10) reflect the contract's private-company recipient, limiting direct public equity exposure despite the large dollar value. The key investment story is the sustained DHS/CBP spending on physical border barriers, which is politically sensitive and subject to funding volatility. Investors should monitor execution risk on the fixed-price contract and policy shifts that could impact future awards, but no immediate bullish or bearish signals for public equities emerge from this data.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 14, 2026

Today's single high-value grant—a $224.7 million obligation to Fisher Sand & Gravel Co. from DHS/CBP for border infrastructure—is entirely civilian and offers limited public equity exposure since the recipient is private. The neutral-conviction signal (strength 5/10) reflects the firm-fixed-price structure that transfers cost risk to the contractor but provides predictable revenue over three years, with 78% already outlaid. The dominant theme is sustained border security investment, though political cycles and policy shifts create funding volatility risk. No defense-related contracts were recorded, leaving defense-sector investors without direct signals from this stream.

1 total filings
· daily

General Federal Contracts — July 14, 2026

The single contract in this period, a $224.7 million firm-fixed-price delivery order awarded to Fisher Sand & Gravel Co. by the Department of Homeland Security (DHS) for border infrastructure construction, is entirely civilian in nature and carries a neutral investment signal. The contract shows strong execution progress with $169.1 million already outlaid, but it represents a high revenue concentration for a private company with no direct public equity exposure. The key risk is political and budgetary volatility surrounding border security funding, which could impact future awards or cost recovery. The highest-conviction signal is the medium pricing risk on a fixed-price contract, which transfers cost overrun risk to the contractor.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 14, 2026

The 7 filings for the S&P 500 Technology sector reveal a bifurcated landscape: IBM's preliminary Q2 2026 results show a mixed picture with Software revenue growing 5% YoY and Red Hat accelerating to 11%, but Infrastructure declining 7% and GAAP gross margins contracting 100 bps. The most significant signal is a wave of insider selling across five companies—Arista Networks ($30.1M CEO sale), Broadcom ($10M CLO sale), Lam Research ($6.12M director sale), Analog Devices ($390K director sale), and Qualcomm ($104K CFO sale)—all executed under Rule 10b5-1 plans, suggesting pre-planned portfolio diversification rather than panic. Period-over-period comparisons highlight IBM's revenue growth deceleration (1% YoY vs prior quarters) and margin compression, while insider activity patterns indicate no sector-wide distress but warrant monitoring for any acceleration. Capital allocation is absent from most filings, but IBM's $5B Lightwell initiative and $10B quantum computing investment signal long-term strategic bets. The lack of forward-looking guidance or scheduled events in most filings limits catalyst calendar building, but the concentrated insider selling in high-growth names (Arista, Broadcom, Lam Research) creates a watch item for Q3 earnings season.

6 high priority 1 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 14, 2026

Today's filings from NASDAQ-100 constituents reveal a concentrated wave of insider selling across the semiconductor sector, with four separate dispositions from Analog Devices, Qualcomm, Broadcom, and Lam Research totaling approximately $16.3 million. While most sales were executed under Rule 10b5-1 plans—suggesting pre-planned portfolio diversification rather than reactive bearishness—the sheer volume and clustering raise a cautionary flag for the chip ecosystem. Notably, Broadcom's Chief Legal Officer sold $10 million in a single transaction, the largest disclosed insider move. In contrast, Costco and a second Broadcom filing show only non-economic gifts, indicating no material change in insider conviction for those names. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A transactions were reported in these filings, limiting the breadth of trend analysis. The dominant theme is a high-conviction insider profit-taking pattern in semiconductors, which investors should weigh against the sector's strong recent performance and elevated valuations.

6 high priority 6 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 14, 2026

The July 14, 2026 batch of 50 filings is dominated by routine institutional ownership disclosures from Dimensional Fund Advisors LP, which filed 37 Schedule 13G amendments covering a broad portfolio of small to mid-cap US equities. The filings reveal a clear pattern of incremental, passive accumulation across a diverse set of sectors, with Dimensional increasing stakes in 10 companies, decreasing in 2, and maintaining or slightly adjusting holdings in the remainder. The most actionable intelligence, however, comes from a small cluster of activist and major shareholder filings. The activist campaign at Phunware (PHUN) is the highest-conviction signal, with a Hong Kong-based fund publicly attacking governance and proposing board change after a 90% stock decline. Gogoro Inc. (GGR) presents a unique governance event following a founder's death, while Great Elm Group (GEG) shows a major shareholder deferring dilution, signaling a cooperative stance. The spin-off of Midera Food Processing (MIDERA) from Middleby (MIDD) created a new 7.5% holder with board representation. Overall, the digest points to a market where passive flows are steady but the real alpha opportunities lie in activist situations and corporate events.

5 high priority 45 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 14, 2026

The S&P 500 Financials sector is experiencing a powerful earnings expansion, with the largest U.S. banks reporting double-digit revenue and profit growth in Q2 2026, driven by surging investment banking fees and robust markets activity. However, this growth is uneven: while Goldman Sachs and JPMorgan posted exceptional results, Wells Fargo's net interest margin contracted sharply, and Citigroup's net credit losses increased. A significant sector-wide theme is the aggressive push into digital assets, highlighted by Morgan Stanley's dual Ethereum and Solana trust filings, signaling institutional adoption is accelerating. Insider activity is overwhelmingly neutral, dominated by routine equity awards at Progressive, but a notable negative signal comes from Robinhood Markets selling shares in its Ventures Fund. The key risk to monitor is margin compression in traditional lending businesses, even as trading and advisory revenues boom, creating a bifurcated environment where capital markets-focused firms outperform retail banks.

24 high priority 8 medium 32 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 14, 2026

The sole filing in today's S&P 500 Energy digest is a Form 4 from Texas Pacific Land Corp (TPL), revealing a nominal insider purchase by its 10% owner, Horizon Kinetics Asset Management. While the transaction size is trivial (1 share at ~$411), the action itself carries a positive signal, as it represents a rare insider buy from a major institutional holder. There are no period-over-period trends, guidance changes, or capital allocation actions to aggregate across the stream, limiting the depth of portfolio-level synthesis. The key takeaway is that despite a lack of material corporate events, the insider activity suggests a baseline of confidence from a significant shareholder. The digest is heavily constrained by the single filing, but the positive sentiment and insider buy provide a modest bullish indicator for TPL in an otherwise quiet energy sector day.

1 high priority 1 total filings